Roivant Sciences Ltd (ROIV)
Roivant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing medicines and enabling technologies. Its pipeline includes IMVT-1402 for several autoimmune and inflammatory conditions, batoclimab for thyroid eye disease, and brepocitinib for immune-mediated diseases such as dermatomyositis and non-infectious uveitis. The company’s lead program is mosliciguat, an inhaled soluble guanylate cyclase activator being studied for pulmonary hypertension associated with interstitial lung disease and related cardiopulmonary conditions. Roivant also works with drug-delivery platforms, including a lipid nanoparticle system and a ligand conjugate platform. The company was founded in 2014 and is based in London, United Kingdom.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ROIV
|
$22.38
|
-35.8% Downside
|
Overvalued
|
$39.32
|
12.9% Upside
|
Fair
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 17, 2026
|
-83.5x
|
5.5x
|
3,032.1x
|
24.491 B
|
21.218 B
|
0.4%
|
78.4%
|
20.4
|
—
|
253.0%
|
